Crossmark

A leap towards enforcing medicines prescribing by generic names in low- and middle-income countries (LMICs): pitfalls, limitations, and recommendations for local drug regulatory agencies

Crossref DOI link: https://doi.org/10.1186/s40545-022-00501-4

Published Online: 2022-12-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Merchant, Hamid A.

Babar, Zaheer-Ud-Din

Hussain, Izhar M.
License Information

Text and Data Mining valid from 2022-12-22

Version of Record valid from 2022-12-22
More Information

Article History

First Online: 22 December 2022

Declarations

:

: Not applicable.

: All authors reviewed and approved the manuscript.

: Dr Hamid A. Merchant (@HamidMerchant) is Subject Lead in Pharmacy at the University of Huddersfield, UK and also holds an adjunct Professorship at the Health Services Academy, Ministry of National Health Services Regulations & Coordination, Government of Pakistan. Dr Izhar M. Hussain (@DrIzharHussain2) is the Director of the Institute of Business & Health Management (IBHM) at the Dow University of Health Sciences (DUHS), Karachi, Pakistan. Both authors have extensive work experience from academia and have also worked in the pharmaceutical industry. Dr Zaheer-Ud-Din Babar is a Professor in Medicines and Healthcare at the University of Huddersfield and have consulted for various public health organisations in his current and previous employments. He is also the Editor-in-Chief of Journal of Pharmaceutical Policy and Practice. Authors have not received any funding to commission or support this work and have no other competing interests to declare.

Document is current

Any future updates will be listed below